Welcome to LookChem.com Sign In|Join Free
  • or
C-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-methylamine is a chemical compound characterized by its molecular formula C9H19NO. It is an amine derivative of 2,2-Dimethyl-tetrahydro-pyran-4-yl-methanol, a synthetic intermediate widely utilized in the pharmaceutical industry. This colorless liquid exhibits a strong amine odor and is recognized for its versatile reactivity and stability in organic synthesis, particularly in the formation of complex molecular structures.

50675-25-7

Post Buying Request

50675-25-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

50675-25-7 Usage

Uses

Used in Pharmaceutical Industry:
C-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-methylamine is used as a reagent for the synthesis of various pharmaceutical drugs. Its unique structure and reactivity contribute to the development of new and innovative medications, enhancing the therapeutic options available to patients.
Used in Agrochemical Industry:
In the agrochemical sector, C-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-methylamine serves as a key reagent in the production of agrochemicals. Its application in this field aids in the creation of effective and targeted solutions for agricultural challenges, such as pest control and crop protection.
Used in Organic Synthesis:
C-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-methylamine is utilized as a valuable chemical in organic synthesis due to its stability and versatile reactivity. It plays a crucial role in the creation of complex molecular structures, which are essential in various chemical and pharmaceutical applications.

Check Digit Verification of cas no

The CAS Registry Mumber 50675-25-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,6,7 and 5 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 50675-25:
(7*5)+(6*0)+(5*6)+(4*7)+(3*5)+(2*2)+(1*5)=117
117 % 10 = 7
So 50675-25-7 is a valid CAS Registry Number.

50675-25-7Relevant academic research and scientific papers

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

-

Page/Page column 76-77, (2012/06/01)

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

-

Page/Page column 83, (2012/06/01)

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

-

Page/Page column 99-100, (2012/08/08)

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

-

Page/Page column 91, (2012/08/08)

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

-

Page/Page column 139-140, (2012/08/08)

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

-

Page/Page column 80-81, (2012/08/08)

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

-

Page/Page column 57-58, (2011/04/14)

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

-

Page/Page column 58-59, (2011/04/14)

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 50675-25-7